Literature DB >> 26207214

The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer.

Zhengfei Zhu1, Xiaolong Fu1.   

Abstract

Radiotherapy (RT) plays an important role in the management of lung cancer. Development of radiation techniques is a possible way to improve the effect of RT by reducing toxicities through better sparing the surrounding normal tissues. This article will review the application of two forms of intensity-modulated radiation therapy (IMRT), fixed-field IMRT and helical tomotherapy (HT) in lung cancer, including dosimetric and clinical studies. The advantages and potential disadvantages of these two techniques are also discussed.

Entities:  

Keywords:  Lung cancer; helical tomotherapy (HT); intensity-modulated radiation therapy (IMRT); radiotherapy (RT)

Year:  2015        PMID： 26207214      PMCID： PMC4483473          DOI： 10.3978/j.issn.2218-6751.2015.01.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  67 in total

Review 1.  Intensity-modulated radiotherapy in the treatment of lung cancer.

Authors:  A Bezjak; R B Rumble; G Rodrigues; A Hope; P Warde
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-06-20       Impact factor: 4.126

2.  Helical tomotherapy radiation leakage and shielding considerations.

Authors:  John Balog; Dan Lucas; Cleber DeSouza; Rick Crilly
Journal:  Med Phys       Date:  2005-03       Impact factor: 4.071

Review 3.  Tomotherapy and other innovative IMRT delivery systems.

Authors:  John D Fenwick; Wolfgang A Tomé; Emilie T Soisson; Minesh P Mehta; T Rock Mackie
Journal:  Semin Radiat Oncol       Date:  2006-10       Impact factor: 5.934

Review 4.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

5.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

6.  The clinical value of non-coplanar photon beams in biologically optimized intensity modulated dose delivery on deep-seated tumours.

Authors:  Brigida C Ferreira; Roger Svensson; Johan Löf; Anders Brahme
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

7.  Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women.

Authors:  C E Land; J D Boice; R E Shore; J E Norman; M Tokunaga
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

8.  Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Min-Jeong Kim; Seung-Gu Yeo; Eun Seok Kim; Chul Kee Min; Pyung Se An
Journal:  Oncol Lett       Date:  2012-12-18       Impact factor: 2.967

9.  Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.

Authors:  Alexander Chi; Pan Ma; Guishan Fu; Gerry Hobbs; James S Welsh; Nam P Nguyen; Si Young Jang; Jinrong Dai; Jing Jin; Ritsuko Komaki
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis.

Authors:  Aiko Nagai; Yuta Shibamoto; Masanori Yoshida; Koji Inoda; Yuzo Kikuchi
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411
View more
  7 in total

1.  Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.

Authors:  Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder
Journal:  Strahlenther Onkol       Date:  2019-03-26       Impact factor: 3.621

2.  Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

Authors:  Shiming Shi; Zhaochong Zeng; Luxi Ye; Yan Huang; Jian He
Journal:  Technol Cancer Res Treat       Date:  2016-08-11

3.  Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer.

Authors:  Yujin Xu; Weiye Deng; Shuangyan Yang; Pu Li; Yue Kong; Ye Tian; Zhongxing Liao; Ming Chen
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

4.  Dynamic changes in T-cell subsets and C-reactive protein after radiation therapy in lung cancer patients and correlation with symptomatic radiation pneumonitis treated with steroid therapy.

Authors:  Lu Bai; Bao-Sen Zhou; Yu-Xia Zhao
Journal:  Cancer Manag Res       Date:  2019-08-22       Impact factor: 3.989

Review 5.  Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members.

Authors:  Jamiluddin Qazi; Kristi A DeHaai; Benjamin M Hawkins; Kara D Romano; Nicholas G Zaorsky; Ronald C Chen; Timothy N Showalter
Journal:  Contemp Clin Trials Commun       Date:  2022-03-19

6.  Dose delivery accuracy on helical tomotherapy for 4-dimensional tumor motion - a phantom study.

Authors:  Raghavendra Holla; David Khanna; V K Sathiya Narayanan
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09

7.  Treatment outcomes of helical tomotherapy for hepatocellular carcinoma in terms of intermediate-dose spillage.

Authors:  Sun Hyun Bae; Kwang Hwan Cho; Young Seok Kim; Sang Gyune Kim; Jeong-Ju Yoo; Jae Myung Lee; Min Hee Lee; Sanghyeok Lim; Jae Hong Jung; Sung Hee Lim
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.